Shanghai-based Ablaze Pharma announced plans to invest an initial $100 million in a new research and development and manufacturing center for targeted radiation therapies (TRTs) in Chengdu’s Wenjiang district. The project follows an agreement with the local government and aims to leverage Sichuan’s nuclear science expertise.
Project Details
The 26,000㎡ facility will focus on developing Ablaze’s five anti-tumor pipeline candidates. The site will host a full industrial chain ecosystem for TRT drugs, including partnerships with other radiopharmaceutical firms. It will also tap into Sichuan’s nuclear science resources, such as the National Engineering Research Center for isotopes and drugs.
Company Background
Founded in 2021, Ablaze Pharma is a clinical-stage firm focused on advancing TRTs for Chinese cancer patients. The company has partnered with U.S.-based RayzeBio to exclusively develop and commercialize a series of radiopharmaceutical products in Greater China.-Fineline Info & Tech
